Mark Schumacher, MD, PhD
Dr. Schumacher is Professor and Chief of the Division of Pain Medicine in the Department of Anesthesia and Perioperative Care, University of California, San Francisco. He has a clinical, research and educational focus on pain medicine with an emphasis on the development of evidence – based pain care into general clinical practice that utilize non-addictive modalities to improve both the quality and safety of analgesic care. Dr. Schumacher is also the Director of the UCSF Pain and Addiction Research Center (PARC) and served on the National Academies of Science Engineering and Medicine Committee, co-authoring the report on “Pain Management and the Opioid Epidemic.” Scientifically, following his collaboration in the cloning of the Capsaicin Receptor (TRPV1), he has led a laboratory dedicated to non-addictive strategies to block the transition from acute to chronic pain through transcriptional blockade. His current NIH-funded research includes: Study of painful Chemotherapy-Induced Peripheral Neuropathy (CIPN) with the aim to develop novel therapeutics and studying Neuro-immune Mechanisms of Analgesia of the Minor Cannabinoids such as CBD as well as its developmental effects on sensory neurons. Throughout his career, he has sought ways to communicate the science and practice of pain medicine including previously directing an NIH Center of Excellence in Pain Education at UCSF.